Meplazumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized immunoglobulin G2 (IgG2) monoclonal antibody directed against CD147 (basigin; BSG; extracellular matrix metalloproteinase inducer; EMMPRIN), with potential immunomodulating activity. Upon administration, meplazumab targets, binds to and inhibits the activity of CD147. This may prevent the binding of the spike protein (SP) of SARS-CoV-2 to CD147 on human host cells. This may prevent SARS-CoV-2's host cell entry through CD147-mediated transport and prevent host cell invasion. This may block SARS-CoV-2 infection. In addition, preventing viral invasion of progenitor/stem cells may enhance lung repair and suppress inflammation. CD147, a highly glycosylated transmembrane protein of the immunoglobulin superfamily expressed on host-cells, including red blood cells (RBCs), T-cells, and stem/progenitor cells, may play a key role in host invasion by SARS-CoV-2.

**Synonyms:** - Ketantin - MEPLAZUMAB - PMZ-201501 - PMZ201501